Skip to main content
Erschienen in: Familial Cancer 2/2012

01.06.2012 | Short Communication

Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients

verfasst von: Muhammad U. Rashid, Sidra Gull, Kashif Asghar, Noor Muhammad, Asim Amin, Ute Hamann

Erschienen in: Familial Cancer | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Women from Pakistan and India are more often diagnosed with early-onset breast cancer than Caucasian women. Given that only 12% of Pakistani women diagnosed with breast cancer at or before 30 years of age have previously been shown to harbor germ line mutations in the breast cancer susceptibility genes BRCA1 and BRCA2, the genetic causes of the majority of early-onset cases are unexplained. Since germ line mutations in the tumor suppressor gene TP53 predispose women to early-onset breast cancer, we assessed the prevalence of TP53 mutations in 105 early-onset breast cancer patients from Pakistan, who had previously been found to be negative for BRCA1 and BRCA2 germ line mutations. The patient group included 67 women diagnosed with early-onset breast cancer at or before age 30 with no family history of breast or ovarian cancer (EO30NFH group) and 38 women diagnosed with breast cancer at or before age 40 with one or more first- or second-degree relatives with breast or ovarian cancer (EO40FH group). Mutation analysis of the complete TP53 coding region was performed using denaturing high-performance liquid chromatography analysis, followed by DNA sequencing of variant fragments. One deleterious mutation, c.499-500delCA in exon 5, was identified in the 105 breast cancer patients (1%). This mutation is novel in the germ line and has not been described in other populations. It was detected in a 28-year-old patient with no family history of breast or ovarian cancer. This mutation is rare as it was not detected in additional 157 recently recruited non-BRCA1 and non-BRCA2-associated early-onset breast cancer patients. Our findings show that TP53 mutations may account for a minimal portion of early-onset breast cancer in Pakistan.
Literatur
1.
Zurück zum Zitat Bhurgri Y (2004) Karachi Cancer Registry Data–implications for the National Cancer Control Program of Pakistan. Asian Pac J Cancer Prev 5:77–82PubMed Bhurgri Y (2004) Karachi Cancer Registry Data–implications for the National Cancer Control Program of Pakistan. Asian Pac J Cancer Prev 5:77–82PubMed
2.
Zurück zum Zitat Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010) Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US–a SEER analysis. BMC Cancer 10:191PubMedCrossRef Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010) Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US–a SEER analysis. BMC Cancer 10:191PubMedCrossRef
3.
Zurück zum Zitat Moran MS, Gonsalves L, Goss DM, Ma S (2011) Breast cancers in US residing Indian-Pakistani versus non-Hispanic White women: comparative analysis of clinical-pathologic features, treatment, and survival. Breast Cancer Res Treat 128:543–551PubMedCrossRef Moran MS, Gonsalves L, Goss DM, Ma S (2011) Breast cancers in US residing Indian-Pakistani versus non-Hispanic White women: comparative analysis of clinical-pathologic features, treatment, and survival. Breast Cancer Res Treat 128:543–551PubMedCrossRef
4.
Zurück zum Zitat Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362PubMed Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362PubMed
5.
Zurück zum Zitat Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238PubMedCrossRef Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238PubMedCrossRef
6.
Zurück zum Zitat Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298–1304PubMed Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298–1304PubMed
7.
Zurück zum Zitat Evans DG, Birch JM, Thorneycroft M, McGown G, Lalloo F, Varley JM (2002) Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet 39:941–944PubMedCrossRef Evans DG, Birch JM, Thorneycroft M, McGown G, Lalloo F, Varley JM (2002) Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet 39:941–944PubMedCrossRef
8.
Zurück zum Zitat Frebourg T, Barbier N, Yan YX et al (1995) Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56:608–615PubMed Frebourg T, Barbier N, Yan YX et al (1995) Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56:608–615PubMed
9.
Zurück zum Zitat Olivier M, Goldgar DE, Sodha N et al (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643–6650PubMed Olivier M, Goldgar DE, Sodha N et al (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643–6650PubMed
10.
Zurück zum Zitat Varley JM, McGown G, Thorncroft M et al (1997) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252PubMed Varley JM, McGown G, Thorncroft M et al (1997) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252PubMed
11.
Zurück zum Zitat Eeles RA, Bartkova J, Lane DP, Bartek J (1993) The role of TP53 in breast cancer development. Cancer Surv 18:57–75PubMed Eeles RA, Bartkova J, Lane DP, Bartek J (1993) The role of TP53 in breast cancer development. Cancer Surv 18:57–75PubMed
12.
Zurück zum Zitat Chompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932–1937PubMedCrossRef Chompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932–1937PubMedCrossRef
13.
Zurück zum Zitat Chompret A, Abel A, Stoppa-Lyonnet D et al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43–47PubMedCrossRef Chompret A, Abel A, Stoppa-Lyonnet D et al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43–47PubMedCrossRef
14.
Zurück zum Zitat Le BC, Bonaiti-Pellie C (1994) A method for estimating cancer risk in p53 mutation carriers. Cancer Detect Prev 18:171–178 Le BC, Bonaiti-Pellie C (1994) A method for estimating cancer risk in p53 mutation carriers. Cancer Detect Prev 18:171–178
15.
Zurück zum Zitat Borresen AL, Andersen TI, Garber J et al (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234–3236PubMed Borresen AL, Andersen TI, Garber J et al (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234–3236PubMed
16.
Zurück zum Zitat Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250–1256PubMedCrossRef Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250–1256PubMedCrossRef
17.
Zurück zum Zitat Lalloo F, Varley J, Ellis D et al (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361:1101–1102PubMedCrossRef Lalloo F, Varley J, Ellis D et al (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361:1101–1102PubMedCrossRef
18.
Zurück zum Zitat Lalloo F, Varley J, Moran A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143–1150PubMedCrossRef Lalloo F, Varley J, Moran A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143–1150PubMedCrossRef
19.
Zurück zum Zitat Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM, Evans HJ (1991) Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer 63:181–184PubMedCrossRef Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM, Evans HJ (1991) Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer 63:181–184PubMedCrossRef
20.
Zurück zum Zitat Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388PubMedCrossRef Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388PubMedCrossRef
21.
Zurück zum Zitat Arcand SL, Maugard CM, Ghadirian P et al (2008) Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat 108:399–408PubMedCrossRef Arcand SL, Maugard CM, Ghadirian P et al (2008) Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat 108:399–408PubMedCrossRef
22.
Zurück zum Zitat Ginsburg OM, Akbari MR, Aziz Z et al (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563–567PubMedCrossRef Ginsburg OM, Akbari MR, Aziz Z et al (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563–567PubMedCrossRef
23.
Zurück zum Zitat Mouchawar J, Korch C, Byers T et al (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian breast cancer family study. Cancer Res 70:4795–4800PubMedCrossRef Mouchawar J, Korch C, Byers T et al (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian breast cancer family study. Cancer Res 70:4795–4800PubMedCrossRef
24.
Zurück zum Zitat Sidransky D, Tokino T, Helzlsouer K et al (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984–2986PubMed Sidransky D, Tokino T, Helzlsouer K et al (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984–2986PubMed
25.
Zurück zum Zitat Cao AY, Jin W, Shi PC, Di GH, Shen ZZ, Shao ZM (2010) Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population. Breast Cancer Res Treat 119:295–303PubMedCrossRef Cao AY, Jin W, Shi PC, Di GH, Shen ZZ, Shao ZM (2010) Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population. Breast Cancer Res Treat 119:295–303PubMedCrossRef
26.
Zurück zum Zitat Rashid MU, Zaidi A, Torres D et al (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 119:2832–2839PubMedCrossRef Rashid MU, Zaidi A, Torres D et al (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 119:2832–2839PubMedCrossRef
27.
Zurück zum Zitat Gross E, Kiechle M, Arnold N (2001) Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Methods 47:73–81PubMedCrossRef Gross E, Kiechle M, Arnold N (2001) Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Methods 47:73–81PubMedCrossRef
28.
Zurück zum Zitat Shimmyo T, Okada A, Hashimoto T et al (2008) Etiologic value of p53 mutation spectra and differences with histology in lung cancers. Cancer Sci 99:287–295PubMedCrossRef Shimmyo T, Okada A, Hashimoto T et al (2008) Etiologic value of p53 mutation spectra and differences with histology in lung cancers. Cancer Sci 99:287–295PubMedCrossRef
29.
Zurück zum Zitat Riedel F, Gotte K, Schwalb J, Schafer C, Hormann K (2000) Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol 120:105–111PubMed Riedel F, Gotte K, Schwalb J, Schafer C, Hormann K (2000) Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol 120:105–111PubMed
30.
Zurück zum Zitat Han ES, Moyer MP, Naylor S, Sakaguchi AY (1991) Mutation in the TP53 gene in colorectal carcinoma detected by polymerase chain reaction. Genes Chromosomes Cancer 3:313–317PubMedCrossRef Han ES, Moyer MP, Naylor S, Sakaguchi AY (1991) Mutation in the TP53 gene in colorectal carcinoma detected by polymerase chain reaction. Genes Chromosomes Cancer 3:313–317PubMedCrossRef
31.
Zurück zum Zitat Mir MM, Dar NA, Gochhait S, Zargar SA, Ahangar AG, Bamezai RN (2005) p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer 116:62–68PubMedCrossRef Mir MM, Dar NA, Gochhait S, Zargar SA, Ahangar AG, Bamezai RN (2005) p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer 116:62–68PubMedCrossRef
32.
Zurück zum Zitat Kropveld A, van Mansfeld AD, Nabben N, Hordijk GJ, Slootweg PJ (1996) Discordance of p53 status in matched primary tumours and metastases in head and neck squamous cell carcinoma patients. Eur J Cancer B Oral Oncol 32B:388–393PubMedCrossRef Kropveld A, van Mansfeld AD, Nabben N, Hordijk GJ, Slootweg PJ (1996) Discordance of p53 status in matched primary tumours and metastases in head and neck squamous cell carcinoma patients. Eur J Cancer B Oral Oncol 32B:388–393PubMedCrossRef
33.
Zurück zum Zitat Yamanoshita O, Kubota T, Hou J et al (2005) DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. Int J Cancer 114:74–79PubMedCrossRef Yamanoshita O, Kubota T, Hou J et al (2005) DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. Int J Cancer 114:74–79PubMedCrossRef
34.
Zurück zum Zitat Mahdavinia M, Bishehsari F, Verginelli F et al (2008) P53 mutations in colorectal cancer from northern Iran: relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol 216:543–550PubMedCrossRef Mahdavinia M, Bishehsari F, Verginelli F et al (2008) P53 mutations in colorectal cancer from northern Iran: relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol 216:543–550PubMedCrossRef
35.
Zurück zum Zitat Sauna ZE, Kimchi-Sarfaty C (2011) Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12:683–691PubMedCrossRef Sauna ZE, Kimchi-Sarfaty C (2011) Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12:683–691PubMedCrossRef
36.
Zurück zum Zitat Bougeard G, Sesboue R, Baert-Desurmont S et al (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45:535–538PubMedCrossRef Bougeard G, Sesboue R, Baert-Desurmont S et al (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45:535–538PubMedCrossRef
37.
Zurück zum Zitat Olivier M, Langerod A, Carrieri P et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157–1167PubMedCrossRef Olivier M, Langerod A, Carrieri P et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157–1167PubMedCrossRef
38.
Zurück zum Zitat Langerod A, Zhao H, Borgan O et al (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9:R30PubMedCrossRef Langerod A, Zhao H, Borgan O et al (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9:R30PubMedCrossRef
Metadaten
Titel
Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients
verfasst von
Muhammad U. Rashid
Sidra Gull
Kashif Asghar
Noor Muhammad
Asim Amin
Ute Hamann
Publikationsdatum
01.06.2012
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2012
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9509-7

Weitere Artikel der Ausgabe 2/2012

Familial Cancer 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.